TY - JOUR
T1 - Pharmacokinetic and clinical studies on cefmenoxime in neonates and premature infants
AU - Sato, Yoshitake
AU - Iwata, Satoshi
AU - Kusumoto, Yutaka
AU - Shiro, Hiroyuki
AU - Oikawa, Tadao
AU - Osano, Mitsuru
PY - 1989/1/1
Y1 - 1989/1/1
N2 - Pharmacokinetic and clinical studies on cefmenoxime (CMX) in neonates and premature infants were conducted. The results are summarized as follows. 1. Intravenous administration of CMX at 20 mg/kg, via bolus injection or 1-hour drip infusion, produced at sufficiently high blood concentration. As it is the case with other cephem antibiotics, the half-life varied with age and tended to become shorter with aging. 2. There were intergroup differences in urinary recovery of the drug, but urinary concentrations were generally high. 3. In the clinical evaluation, 12 out of 15 cases which were evaluable for efficacy were rated “excellent” or “good”. 4. Side effects were evaluated in 27 cases. A bleeding tendency was found in 1 case, eosinophilia in 1 case, elevated GOT in 1 case, and positive PIVKA II in 4 cases. It is, therefore, concluded that CMX is a highly useful drug for the treatment of bacterial infections in neonates and premature infants.
AB - Pharmacokinetic and clinical studies on cefmenoxime (CMX) in neonates and premature infants were conducted. The results are summarized as follows. 1. Intravenous administration of CMX at 20 mg/kg, via bolus injection or 1-hour drip infusion, produced at sufficiently high blood concentration. As it is the case with other cephem antibiotics, the half-life varied with age and tended to become shorter with aging. 2. There were intergroup differences in urinary recovery of the drug, but urinary concentrations were generally high. 3. In the clinical evaluation, 12 out of 15 cases which were evaluable for efficacy were rated “excellent” or “good”. 4. Side effects were evaluated in 27 cases. A bleeding tendency was found in 1 case, eosinophilia in 1 case, elevated GOT in 1 case, and positive PIVKA II in 4 cases. It is, therefore, concluded that CMX is a highly useful drug for the treatment of bacterial infections in neonates and premature infants.
UR - http://www.scopus.com/inward/record.url?scp=0024806830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024806830&partnerID=8YFLogxK
U2 - 10.11553/antibiotics1968b.42.2582
DO - 10.11553/antibiotics1968b.42.2582
M3 - Article
C2 - 2614915
AN - SCOPUS:0024806830
SN - 0368-2781
VL - 42
SP - 2582
EP - 2592
JO - The Journal of antibiotics. Ser. B
JF - The Journal of antibiotics. Ser. B
IS - 12
ER -
